# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

> **NCT04601844** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pozelimab
- **DRUG:** Cemdisiran

## Key facts

- **NCT ID:** NCT04601844
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2021-07-23
- **Final completion:** 2021-07-23
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04601844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04601844, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04601844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*